Hims vs MangoRx: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher & Publisher
Hims beats MangoRx overall, scoring 7.9/10 vs 7.5/10. Hims is more affordable at $149/mo vs $299/mo. Choose Hims for men who want a well-known publicly-traded brand and fda-appr. Choose MangoRx for needle-phobic users who want oral-only glp-1 tablets from a .
A side-by-side look at Hims and MangoRx to help you decide. We compare them on:
- •Starting price per month
- •Our overall score, out of 10
- •Medication type, brand-name or compounded
- •Whether they accept insurance
- •Who each one is best for
Hims
#7 of 53The household name in men's telehealth, publicly traded as Hims & Hers Health (NYSE: HIMS). In 2026 Hims added FDA-approved brand-name Wegovy (injection and pill) and Ozempic through a direct Novo Nordisk partnership, and has since exited compounded semaglutide for new patients, so the retail lineup is FDA-approved brand only. Its parent still reports offering access to compounded GLP-1 medications on a limited scale (Q2 2026 results, filed with the SEC August 10, 2026). Brand recognition and product breadth are real strengths. The trade-off: Hims' verified Trustpilot rating is 3.0 stars across 8,286 reviews (May 2026), significantly below smaller competitors like Henry Meds (4.5) or Eden Health (4.5). The 1-star pool is 28%, the highest 1-star rate in our table, clustered around subscription/billing complaints.
Visit HimsMangoRx
#24 of 53Multi-service telehealth platform offering compounded GLP-1 alongside other health services.
Visit MangoRx| Feature | Hims | MangoRx |
|---|---|---|
| Why each one | The only publicly-traded men's telehealth (NYSE: HIMS) with FDA-approved Wegovy via direct Novo Nordisk partnership. Brand-name access plus SEC accountability, but balanced against a 3.0 Trustpilot rating that lags peers. | Oral dissolving tablets exclusively (zero injections) from a publicly traded company (NASDAQ: MGRX) with SEC-level financial transparency. |
| Our Score | 7.9/10 | 7.5/10 |
| Starting Price | $149/mo | $299/mo |
| Medication Type | Both | Compounded |
| Insurance Accepted | No | No |
| Best For | Men who want a well-known publicly-traded brand and FDA-approved Wegovy through the 2026 Novo Nordisk partnership, but should know going in that Hims' customer-experience signal is weaker than smaller competitors | Needle-phobic users who want oral-only GLP-1 tablets from a publicly traded company |
| Watch out for | Pending federal enforcement action. On July 29, 2026 the FTC, joined by Utah and California acting through Los Angeles County Counsel, filed a complaint against Hims & Hers Health, Inc. in the U.S. District Court for the Northern District of California, alleging violations of the FTC Act and the Restore Online Shoppers' Confidence Act over subscription billing, cancellation friction, and sharing consumer health information with advertising platforms. Case status is Pending. These are allegations, not findings, and Hims has not been found liable. | Oral semaglutide at $299/mo runs 2-3x injectable alternatives ($99-149/mo). The premium only makes sense if needles are a hard no for you. |
| Ranking | #7 | #24 |
| Get started | Visit Hims | Visit MangoRx |
Pros & Cons Compared
Hims
Pros
- +Publicly traded company (NYSE: HIMS), SEC-filed financials, regulatory accountability that private competitors don't have.
- +2026 Novo Nordisk partnership, FDA-approved Wegovy injection, Wegovy pill, and Ozempic now available directly through Hims. Real brand-name access from a single platform.
- +$199/mo all-inclusive for compounded semaglutide, including consultations and shipping.
- +Polished app and web experience, among the best user interfaces in men's telehealth.
- +8,286 verified Trustpilot reviews is the second-largest review volume in our table (after Henry's 12,461), significant real-world adoption.
Cons
- −Pending federal enforcement action. On July 29, 2026 the FTC, joined by Utah and California acting through Los Angeles County Counsel, filed a complaint against Hims & Hers Health, Inc. in the U.S. District Court for the Northern District of California, alleging violations of the FTC Act and the Restore Online Shoppers' Confidence Act over subscription billing, cancellation friction, and sharing consumer health information with advertising platforms. Case status is Pending. These are allegations, not findings, and Hims has not been found liable.
- −Trustpilot rating is 3.0 stars / 8,286 reviews (May 2026), significantly below Henry Meds (4.5), Eden Health (4.5), Yucca Health (4.6), MEDVi (4.4). The lowest customer-experience signal of any major brand we track.
- −28% of Trustpilot reviews are 1-star, the highest 1-star rate in our table. Top complaint themes: subscription handling, unexpected charges, customer service responsiveness.
- −Hims reviews span ALL their products (ED, hair loss, mental health, weight loss), not just GLP-1. But the rating still applies because most users don't separate experiences by product.
- −'Hims Oral Kit' is NOT a GLP-1, it's a non-GLP-1 metabolic combination (metformin + bupropion + topiramate + B12 + naltrexone). Easy to confuse with their compounded semaglutide. Read the product page carefully before signing up.
- −Cash-pay only, Hims does not bill insurance, so an insured buyer may do better on a copay.
- −Generic high-volume support, large patient base means less personalized attention than smaller competitors.
MangoRx
Pros
- +Oral dissolving tablets exclusively, zero injections for any GLP-1 option
- +Publicly traded on NASDAQ (MGRX), SEC-required financial transparency that private competitors can't match
- +Semaglutide tablet includes Vitamin B6 to help reduce nausea during treatment
- +Free 100% online consultation with no video call required
Cons
- −Oral semaglutide at $299/mo runs 2-3x injectable alternatives ($99-149/mo). The premium only makes sense if needles are a hard no for you.
- −Early-stage public company with limited revenue; the same SEC filings that provide transparency also show the financial uncertainty reflected in the stock.
- −Oral tablets are the only format, with no injectable option if you want higher bioavailability. If you may switch to injections later, pick a platform that carries both.
Our Verdict
Hims edges out MangoRx with a score of 7.9/10 vs 7.5/10. If budget is your priority, Hims is from $149/mo compared to MangoRx from $299/mo. Hims offers both brand-name and compounded medications, giving you more flexibility. Choose Hims if you want: men who want a well-known publicly-traded brand and fda-approved wegovy through the 2026 novo nordisk partnership, but should know going in that hims' customer-experience signal is weaker than smaller competitors. Choose MangoRx if you want: needle-phobic users who want oral-only glp-1 tablets from a publicly traded company.
Cheapest in our index
Embody
$69/mo flat rate · 7.3/10 · Compounded
Both Hims and MangoRx start above the cheapest program we track. Across all 53 providers in our index, that floor is Embody at a flat $69/mo, the same rate at every dose, price checked July 31, 2026. It scores 7.3/10 and is not the highest-scored provider in our full rankings, so this is a cost floor rather than a recommendation. Worth knowing before you decide.
Read Full Reviews
Related comparisons
Other matchups readers comparing Hims or MangoRx tend to look at next.
- Hims vs MEDVi$179/mo
- Hims vs Found$129/mo
- Hims vs AgelessRx$199/mo
- MangoRx vs Direct Meds GLP-1$297/mo
- MangoRx vs Breeze Meds$199/mo
- MangoRx vs Willow$299/mo
Not sure which one is right for you?
Answer a few quick questions and we'll match you to the best GLP-1 provider for your needs. Or keep exploring below.
Our pick of these two: Hims · 7.9/10